Farallon Capital Management LLC Protagonist Therapeutics, Inc Transaction History
Farallon Capital Management LLC
- $19.9 Billion
- Q3 2024
A detailed history of Farallon Capital Management LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Farallon Capital Management LLC holds 5,861,006 shares of PTGX stock, worth $230 Million. This represents 1.32% of its overall portfolio holdings.
Number of Shares
5,861,006
Previous 5,840,773
0.35%
Holding current value
$230 Million
Previous $202 Million
30.15%
% of portfolio
1.32%
Previous 0.98%
Shares
23 transactions
Others Institutions Holding PTGX
# of Institutions
248Shares Held
56.7MCall Options Held
76.3KPut Options Held
114K-
Black Rock Inc. New York, NY5.76MShares$226 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$213 Million3.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$166 Million0.0% of portfolio
-
State Street Corp Boston, MA3.18MShares$125 Million0.01% of portfolio
-
Johnson & Johnson New Brunswick, NJ2.45MShares$96.3 Million35.09% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.93B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...